Sacubitril‐Valsartan in a routine community population: attention to volume status critical to achieving target dose

Sacubitril‐Valsartan in a routine community population: attention to volume status critical to achieving target dose

Abstract Aims In the PARADIGM‐heart failure trial, sacubitril‐valsartan demonstrated a reduction in heart failure admissions and reduced all‐cause mortality in patients with heart failure with reduced ejection fraction. Although real world data have shown similar benefits regarding efficacy and safe...

Full description

Bibliographic Details
Main Authors: Rebabonye B. Pharithi, Maria Ferre‐Vallverdu, Alan S. Maisel, Eoin O'Connell, Myra Walshe, Claire Sweeney, James Barton, Kathrine McDonald, Daniel O'Hare, Chris Watson, Joe Gallagher, Mark Ledwidge, Kenneth McDonald
Format: Article
Language:English
Published: Wiley 2020-02-01
Series:ESC Heart Failure
Subjects:
Heart failure
HF‐rEF
Sacubitril‐Valsartan
Diuretic dose decrease
Target dose
Real world
Online Access:https://doi.org/10.1002/ehf2.12547

Internet

https://doi.org/10.1002/ehf2.12547

Similar Items